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Abstract
Background: Approximately 91% of drugs are imported, some of which are quite expensive and unaffordable for the majority of the population. The 
process of drug development, i. e. the pathway from synthesis of active substance to drug, its implementation in the clinic, is quite complicated and 
long-lasting, of great responsibility and particularly costly, requires enormous investment. The manufacture and implementation of the medicine in the 
medical practice creates great difficulties in starting it. Pharmaceutical manufacturing companies from the country with modest profitability are unable 
or unwilling to invest financial resources in scientific research – an important stage in the development of medicines and in ensuring the beneficial 
activity of the concerned institutions. 
Conclusions: National industry must be focused on the modern manufacturing medicine, competitive and effective medicines from local raw material 
and first of all on the needs of the health system in the country. The situation requires insistence and can only be improved by a joint activity of specialists 
in many fields (production, distribution and rational use) and strengthening the research-development and coordination forces of the scientific activities 
in the country for research, development and implementation of new native original drugs, mainly based on local raw materials. Thus, in finalizing the 
analysis of the role of the pharmaceutical industry in the economic development of the state, it is necessary to mention the important social aspect of it, 
the close interrelation with other branches of industry, as well as the high innovation and investment capability.
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Introduction
The contemporary pharmaceutical industry is the nuc-
leus of the pharmaceutical branch and one of the strate-
gically important and strategically developed economic 
segments of each state [1, 2, 3]. Generally, high and stable 
production growth rates are characteristic of the branch, 
little dependent on economic ups and downs [4].
It is well known that in the 21st century medicine came 
in with a vigorous arsenal of medicines and that the world 
pharmaceutical industry is currently producing tens of 
thousands of pharmaceutical preparations. More than 5 
thousand of them are registered in the Republic of Moldova 
and authorized for use in medical practice in the country. 
The nomenclature of medicines used in medical practice 
has been renewed by 62-75%, so the contemporary physi-
cian has an enormous number of drugs for the prophylaxis 
and treatment of the most diverse conditions [5, 6, 7, 8].
Supplying quality, effective, safe and affordable medi-
cines greatly determines the viability of the healthcare sys-
tem of the country. The state of the pharmaceutical field 
has a clear influence on the health, insurance, financing, 
employment and other spheres, and also contributes to the 
development of mutual cooperation with other fields of in-
dustry (chemical, machine building, agriculture, biotech-
nology, military industry complex and others) [4].
In addition, the pharmaceutical industry invites contri-
butions to research and development, to the development 
of innovative potential, trade relations and the creation of 
technological infrastructure [9].
Domestic pharmaceutical production by 10 authorized 
manufacturers in 2015 of 804 authorizations, 13% or 104 
were indigenous products, in 2016 of 1028 authorizations, 
only 9% or 92 were autochthonous products [10].
Thus, about 91% of drugs are imported, some of which 
are quite expensive and unaffordable for the majority of the 
population. 9% of the pharmaceutical products in the coun-
try are generic (reproduced) and only 14 names of drugs 
proposed by the country's researchers are native, previously 
registered, with antiviral, anti-inflammatory, antihypoten-
sive, and antiseptic actions, etc., but unfortunately not all 
are produced.
In this situation, the lack of essential medicines, of 
course, is compensated by expensive imports, through ex-
pensive drugs, less accessible to the population. Today we 
import medicines from 62 countries (343 companies). In 
2013, pharmaceuticals and parapharmaceutical products 
were imported in the amount of $241.74 million, $271.95 
million in 2014, $339.39 million in 2015, and in the Repub-
lic of Moldova during this period were manufactured drugs 
amounting to 12.3-32.7 million dollars (fig. 1).
The volume of sales (external) amounted in 2013 to 
13.75 million dollars, in 2014 – 11.95 million dollars, in 
2015 – 26.47 million dollars. This has demonstrated the low 
level of national pharmaceutical industry and directly con-
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tributed to the development of other countries' pharmaceu-
tical industries [10].
According to the volume of imports on the names of 
medicines, the first 10 places are: medicinal coal, sodium 
chloride, Valeriana officinalis extract, acetylsalicylic acid, 
citramon, sea buckthorn oil, mucaltin, injectable water, 
naphthasin, etc., less essential preparations, when certain 
requirements are advanced to medicinal products presented 
on the pharmaceutical market: to be effective, safe, quality 
and affordable. We import a lot and expensive, we produce 
less, not totally according to GMP and production is not re-
quired for export - we produce for us.
The pharmaceutical industry includes science and pro-
duction enterprises specializing in the synthesis of syn-
thetic drugs, preparations of vegetable raw materials, vita-
mins, enzymes, antibiotics, endocrine preparations, blood 
substitutes, galenical preparations and bacterial medicinal 
products [11]. It is well known that no country in the world 
produces the whole arsenal of drugs; at the same time any 
country tends to develop its own pharmaceutical industry, 
for the following reasons:
·	Guaranteeing the population with essential medi-
cines;
·	Creating new jobs;
·	 Improving the economy of the country, because the 
pharmaceutical industry around the world is one of 
the most cost-effective.
The pharmaceutical industry is one of the most science-
intensive and high-tech sectors of the economy. Worldwide 
pharmaceutical manufacturers’ spending on research and 
development in this field is 15-20% of the profit [12]. Thus, 
the USA pharmaceutical research spending represents 25% 
of the overall costs for research and development, England 
– 24%, France – 13.8%, Japan – 7.5% [13, 14]. The pharma-
ceutical industry is characterized by the technical and eco-
nomical particularities that influence its functionality: high 
labor productivity, small volume of production, systematic 
renovation of the nomenclature of manufactured medici-
nal preparations, lasting production cycle, completeness 
of technological products, high requirements for quality of 
production [11].
The drug development process, i.e. the pathway from 
drug-to-drug synthesis, to its implementation in the clinic, 
is quite complicated and long-lasting (10-12 years), of great 
responsibility and costly, requires enormous investment. The 
total cost of the research project exceeds US $ 350 million 
(fig. 2).
Fig. 2.  The process of clinical research of new drugs  
(typically exceeding 10 years).
This process includes several stages of preclinical and 
clinical assessments, requires the participation and collabo-
ration of specialists (chemists, pharmacists, pharmacists 
and clinicians) in many fields, the application of quite so-
phisticated contemporary methodologies and technologies.
A special role belongs to the pharmacological research, 
the idea as such and the detection of the actions and the 
basic effects of the new substances, which subsequently gen-
erate the pharmaceutical activities, the clinical research, and 
the manufacturing and implementation technologies.
Manufacture and implementation in medical practice 
are two final stages of the complicated drug development 
process, which creates great difficulties in starting it.
The contemporary pharmaceutical industry relies on a 
considerable volume of fundamental scientific research, us-
ing chemical synthesis, biotechnology, genetic engineering 
and others in its arsenal. For these reasons, drug compa-
nies invest in developing synthesis, performing preclinical 
and clinical assessments, improving technology, and imple-
menting new quality control methods around 20-25% of 
revenue.
State-owned pharmaceutical companies, all joint-stock 
companies, LLCs, manufacturing companies in the country 
are currently involved, as far as possible, in the reproduction 
of less important drugs, approved and used many years ago, 
especially from imported raw material, cheap, suspected to 
be valid and not local (e. g. hydrogen peroxide, iodine solu-
tion, brilliant green, ascorbic acid, analgin, nistatin, novo-
caine etc). We found that no native enterprise is working 
with scientific researchers to develop new drugs.
Drug-producing companies in the country with mod-
est profitability are unable or unwilling to invest financial 
resources in scientific research – an important stage in the 
development of medicines and ensuring the beneficial ac-
tivity of the institutions concerned.
The national industry must be geared towards develop-
Fig. 1.  The dynamics of the import of medicines for 2013-2016.
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ing modern, competitive and efficient medicinal products 
from local raw material and the main one to the needs of the 
health system of the country.
However, we will try to bring to the attention of special-
ists trained in drug development, collaborators of institu-
tions interested in and involved in solving the problem of 
developing and implementing pharmaceutical preparations 
for ensuring the health system with essential medicines and 
accessible to the population, finding ways of significantly re-
ducing the import monopoly of medicines and developing 
the national pharmaceutical market.
During the last few years, in several institutions of the 
Academy of Sciences of Moldova (ASM) and in the Nicolae 
Testemitsanu State University of Medicine and Pharmacy 
were researched various active biological substances, pos-
sessing antidepressive, antihypotensive, hepatoprotective, 
immunomodulating and biostimulating, antimicrobial and 
antifungal, regenerative and cytoprotective, used in the 
treatment of cardiovascular, gastrointestinal, infectious, im-
munodeficiency diseases, etc. But unfortunately these sci-
entific achievements are slowly evolving into the stage of 
microproduction (experimental pilot) and mass production 
with subsequent implementation in practice. For our coun-
try, the issue of using existing natural sources and the imple-
mentation of domestic pharmaceutical products in medical 
practice is extremely important.
The Republic of Moldova has a considerable potential of 
scientists in the field of scientific, academic and university 
institutions, local raw materials necessary for the develop-
ment and implementation of new medicines. This is con-
firmed by the results of the scientific researches carried out 
under the State Program «Elaboration and implementation 
of new pharmaceutical preparations based on the use of lo-
cal raw materials for the years 2007-2010» [15] elaborated 
by the ASM, and continued in subsequent periods, which 
determined the necessity of:
	Forming the scientific basis of development of the 
national pharmaceutical industry by implementing 
in the production of new original medicinal, vegetal, 
animal, entomological and synthetic medicinal prepa-
rations based on local raw materials and creation of 
new jobs;
	By technologies of synthesis and obtaining biologically 
active substances from the local vegetal, animal, ento-
mological and synthetic raw material from industrial 
waste present in enormous quantities in the country 
(seeds, kernels etc.) to develop and research antibacte-
rial and antifungal drugs of new generations, anti-ath-
erogenic preparations of algal origin, various types of 
oils (with regenerative and cytoprotective properties), 
dyes, astringent and adsorbing substances, lipo-and 
water-soluble antioxidants, antiviral, immunomodu-
latory and hepatoprotective products: all necessary for 
the treatment of diseases and pathological conditions 
(immunodeficiency, etc.);
	The expansion of preclinical and clinical scientific re-
search in the field of medicine with the rational use 
of the intellectual potential of the country and the en-
dowment of the bases and scientific research centers 
with modern and efficient equipment;
	Rational alignment to the strategy for the development 
of scientific research in the field of medicines and the 
pharmaceutical industry with respect to the require-
ments and good practice rules (GLP, GCP, GMP etc) 
established by international bodies in the field and 
timing of actions using rational and well-grounded 
human, financial and material resources available;
	Centralizing research and development activity of the 
pharmaceutical industry by setting up an accredita-
tion center for all (state and private) manufacturing 
companies, coordinating their work (including state 
order), implementing GMP, protecting and support-
ing the manufacturer, accomplishing production in-
side and outside the country.
All that is mentioned is only one measure – how could 
science, including scientific research in the field, contrib-
ute to the expansion of the domestic drugs problem in our 
country?
The elaboration and approval of the National Program of 
Scientific Research in the field of medicine and the continu-
ous development of the pharmaceutical industry in Mol-
dova will contribute to:
	Strengthening the research and development forces 
and coordinating the scientific activities in the coun-
try in order to research, develop and implement new 
native drugs, mainly based on local raw materials;
	Excluding the unwanted distances between scientists 
and producers (pharmaceutical industry) – working 
in the interests of the health system;
	Increasing the range of less expensive (indigenous) 
medicines and providing medical institutions and 
population, including socially vulnerable, with first 
quality, harmless, effective and affordable medicines;
	A significant reduction in the cost of purchased medi-
cines and the cost of treatment – import control, pro-
ducer support;
	Improving the country’s economy, because the phar-
maceutical industry is one of the most cost-effective;
	Orientation towards the production of competitive 
and efficient products at the necessity of the health 
system in the country [5, 6, 7, 10].
But the healthcare situation in the country is far more 
difficult (immense, but unstable and irresponsible import 
of drugs, less accessible to the population, lack of effective 
native medicines, irrational and ungainly use of medicines, 
poorly developed national pharmaceutical industry, lack 
of scientific basis for manufacturing enterprises and other 
problems).
This situation requires insistence and can only be im-
proved by a joint activity of specialists in many fields (pro-
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duction, distribution and rational use), concurrent ac-
tivity - what today needs to be well organized, essentially 
restructured and strengthened. In order to help to remedy 
the situation in the field of domestic medicine and the na-
tional pharmaceutical industry, some scientific opportuni-
ties for improvement have been resorted to, and have been 
supported by ASM and P.I. The Expert Advisory Council of 
the ASM adopted the project for young researchers – «New 
Perspective Drugs» (2017-2018), the State Program «New 
Autochthonous Drugs in Optimizing the Treatment» (2018-
2021), the technology transfer project, ”Autochthonous An-
tihypotensives – New Emergency Medicines (Production 
and Implementation)” (2018-2019) and others.
Conclusions
Supplying quality, effective, safe and affordable medi-
cines greatly determines the viability of the healthcare sys-
tem in the country. The accessibility, quality, efficacy and 
harmlessness of drugs is the priority policy of the State in 
the social sphere, contributing to increasing the life of the 
population and enhancing its well-being. The national in-
dustry must be oriented towards the manufacture of mod-
ern, competitive and efficient medicines from the local raw 
material and mainly to the needs of the health system in 
the country. The situation requires insistence and can only 
be improved by a joint activity of specialists in many fields 
(production, distribution and rational use) and strength-
ening the research-development and coordination forces 
of the scientific activities in the country for research, de-
velopment and implementation new native original drugs, 
mainly based on local raw materials. Thus, in finalizing the 
analysis of the role of the pharmaceutical industry in the 
economic development of the state, it is necessary to men-
tion the important social aspect of it, the close interrelation 
with other branches of industry, as well as the high innova-
tion and investment capability.
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